|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.66 CNY | +0.66% |
|
+3.16% | +9.17% |
| 30/25/30 | Wuhan Keqian Biology Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025 | CI |
| 30/25/30 | Wuhan Keqian Biology Gains Approval for Pig Vaccine | MT |
| Capitalization | 772.88Cr 111Cr 94Cr 88Cr 82Cr 152.43Cr 10TCr 161.57Cr 1TCr 397.01Cr 4.81TCr 416.21Cr 407.69Cr 18TCr | P/E ratio 2025 * |
17.4x | P/E ratio 2026 * | 15.7x |
|---|---|---|---|---|---|
| Enterprise value | 772.88Cr 111Cr 94Cr 88Cr 82Cr 152.43Cr 10TCr 161.57Cr 1TCr 397.01Cr 4.81TCr 416.21Cr 407.69Cr 18TCr | EV / Sales 2025 * |
6.95x | EV / Sales 2026 * | 6.03x |
| Free-Float |
24.25% | Yield 2025 * |
3.06% | Yield 2026 * | 1.98% |
| 1 day | +0.66% | ||
| 1 week | +3.16% | ||
| Current month | +9.17% | ||
| 1 month | +6.86% | ||
| 3 months | -1.48% | ||
| 6 months | -2.06% | ||
| Current year | +9.17% |
| 1 week | 16.07 |  | 16.68 |
| 1 month | 15.21 | | 16.68 |
| Current year | 15.27 | | 16.68 |
| 1 year | 13.24 | | 20.39 |
| 3 years | 11 | | 32 |
| 5 years | 11 | | 46.18 |
| 10 years | 11 | | 51.11 |
| Manager | Title | Age | Since |
|---|---|---|---|
Mu Lin Chen
CEO | Chief Executive Officer | 38 | 04/06/2018 |
Ming Zhong
DFI | Director of Finance/CFO | 43 | 01/09/2014 |
Gao Yuan Xu
CTO | Chief Tech/Sci/R&D Officer | 50 | 11/11/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Qi Gai He
BRD | Director/Board Member | 60 | 21/09/2014 |
Liu Rong Fang
BRD | Director/Board Member | 57 | 01/01/2001 |
Mei Zhou Wu
BRD | Director/Board Member | 62 | 01/01/2001 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.66% | +3.16% | +26.12% | -33.12% | 110.11Cr | |
| -0.28% | -0.48% | -25.70% | -25.61% | 5.48TCr | |
| -2.05% | -0.53% | +102.32% | +84.43% | 1.24TCr | |
| +1.05% | +6.68% | -17.84% | +9.11% | 418.73Cr | |
| -0.82% | +1.82% | +20.17% | +32.66% | 360.77Cr | |
| -1.42% | -1.48% | +171.94% | +66.03% | 275.82Cr | |
| -1.81% | -8.07% | -27.03% | -7.89% | 168.67Cr | |
| -6.25% | -5.02% | +78.37% | +152.66% | 168.66Cr | |
| -0.39% | +1.14% | +17.06% | +1.65% | 133.24Cr | |
| -0.59% | +7.88% | +34.12% | -34.13% | 125.07Cr | |
| Average | -1.19% | -1.05% | +37.95% | +24.58% | 848.1Cr | |
| Weighted average by Cap. | -0.68% | -0.49% | +6.02% | +1.73% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 111.22Cr 16Cr 14Cr 13Cr 12Cr 22Cr 1.47TCr 23Cr 143.91Cr 57Cr 692.9Cr 60Cr 59Cr 2.52TCr | 128.21Cr 18Cr 16Cr 15Cr 14Cr 25Cr 1.69TCr 27Cr 165.88Cr 66Cr 798.71Cr 69Cr 68Cr 2.91TCr |
| Net income | 44Cr 6.26Cr 5.33Cr 4.94Cr 4.61Cr 8.6Cr 575.28Cr 9.11Cr 56Cr 22Cr 271.62Cr 23Cr 23Cr 988.04Cr | 49Cr 7.1Cr 6.04Cr 5.6Cr 5.23Cr 9.76Cr 652.78Cr 10Cr 64Cr 25Cr 308.21Cr 27Cr 26Cr 1.12TCr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | 16.66 ¥ | +0.66% | 26,74,719 |
| 22/26/22 | 16.55 ¥ | +0.79% | 26,72,367 |
| 21/26/21 | 16.42 ¥ | +0.06% | 23,80,952 |
| 20/26/20 | 16.41 ¥ | -0.06% | 30,45,655 |
| 19/26/19 | 16.42 ¥ | +1.67% | 28,30,875 |
End-of-day quote Shanghai S.E., January 23, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- 688526 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition